In vitro data indicated that VIP treatment decreases both LPS- and TNF-induced expression of TLR4 in RA-SF, whereas it has no effect on the elevated constitutive expression of TLR2 and TLR4 [142,144]. Here, TLR4 is linked to rheumatoid arthritis.